Antidepressants in the treatment for chronic low back pain: Questioning the validity of meta-analyses

Pain Practice

Volumn 14, Issue 2, 2014, Pages

  Williamson, Owen D ^a,b   Sagman, Doron ^c   Bruins, Robert H ^c   Boulay, Luc J ^c   Schacht, Alexander ^d  

^a FRASER HEALTH AUTHORITY   (Canada)

^b MONASH UNIVERSITY   (Australia)

^c ELI LILLY AND COMPANY   (United States)

^d LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

Antidepressants; Chronic low back pain; Duloxetine; Meta analysis; Systematic review

Indexed keywords

ANTIDEPRESSANT AGENT; DULOXETINE;

ANALGESIC ACTIVITY; ARTICLE; BRIEF PAIN INVENTORY; HUMAN; LOW BACK PAIN; META ANALYSIS (TOPIC); PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION;

ANTIDEPRESSANTS; CHRONIC LOW BACK PAIN; DULOXETINE; META-ANALYSIS; SYSTEMATIC REVIEW;

ANALGESICS; ANTIDEPRESSIVE AGENTS; HUMANS; LOW BACK PAIN; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVIEW LITERATURE AS TOPIC; THIOPHENES;

EID: 84893648677     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/papr.12119     Document Type: Article

References (43)

1. Spitzer WO, Leblanc FE. Scientific approach to the assessment and management of activity-related spinal disorders. A monograph for clinicians. Report of the Quebec Task Force on Spinal Disorders. Spine (Phila Pa 1976). 1987;12:S1-S59.
2. Chou R, Huffman LH, American Pain Society, American College of Physicians. Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med. 2007;147:505-514.
3. National Institute for Health and Clinical Excellence (NICE). Low back pain: early management of persistent non-specific low back pain (full guideline). May 2009. http://www.nice.org.uk/nicemedia/pdf/cg88fullguideline.pdf (accessed October 5, 2013).
4. Toward Optimized Practice (TOP). Guideline for the Evidence-Informed Primary Care Management of Low Back Pain. 2nd ed. Edmonton, AB, Canada; Toward Optimum Practice; 2011. http://www.topalbertadoctors.org/cpgs/885801 (accessed October 5, 2013).
5. Kuijpers T, van Middelkoop M, Rubinstein SM, et al. A systematic review on the effectiveness of pharmacological interventions for chronic non-specific low-back pain. Eur Spine J. 2011;20:40-50.
6. Salerno SM, Browning R, Jackson JL. The effect of antidepressant treatment on chronic back pain: a meta-analysis. Arch Intern Med. 2002;162:19-24.
7. Schnitzer TJ, Ferraro A, Hunsche E, Kong SX. A comprehensive review of clinical trials on the efficacy and safety of drugs for the treatment of low back pain. J Pain Symptom Manage. 2004;28:72-95.
8. Staiger TO, Gaster B, Sullivan MD, Deyo RA. Systematic review of antidepressants in the treatment of chronic low back pain. Spine (Phila Pa 1976). 2003;28:2540-2545.
9. Urquhart DM, Hoving JL, Assendelft WW, Roland M, van Tulder MW. Antidepressants for non-specific low back pain. Cochrane Database Syst Rev. 2008;1:CD001703.
10. Alcoff J, Jones E, Rust P, Newman R. Controlled trial of imipramine for chronic low back pain. J Fam Pract. 1982;14:841-846.
11. Atkinson JH, Slater MA, Capparelli EV, et al. Efficacy of noradrenergic and serotonergic antidepressants in chronic back pain: a preliminary concentration-controlled trial. J Clin Psychopharmacol. 2007;27:135-142.
12. Atkinson JH, Slater MA, Wahlgren DR, et al. Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity. Pain. 1999;83:137-145.
13. Atkinson JH, Slater MA, Williams RA, et al. A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain. Pain. 1998;76:287-296.
14. Dickens C, Jayson M, Sutton C, Creed F. The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain. Psychosomatics. 2000;41:490-499.
15. Goodkin K, Gullion CM, Agras WS. A randomized double blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome. J Clin Psychopharmacol. 1990;10:269-278.
16. Hameroff SR, Weiss JL, Lerman JC, et al. Doxepin's effects on chronic pain and depression: a controlled study. J Clin Psychiatry. 1984;45(3 Pt 2):47-53.
17. Jenkins DG, Ebbutt AF, Evans CD. Tofranil in the treatment of low back pain. J Int Med Res. 1976;4:28-40.
18. Katz J, Pennella-Vaughan J, Hezzel RD, Kanazi GE, Dworkin RH. A randomized, placebo-controlled trial of Bupropion sustained release in chronic low back pain. J Pain. 2005;6:656-661.
19. Pheasant H, Bursk A, Goldfarb J, Azen SP, Weiss JN, Borelli L. Amitriptyline and chronic low-back pain: a randomized double-blind crossover study. Spine (Phila Pa 1976). 1983;8:552-557.
20. Schreiber S, Vinokur S, Shavelzon V, Pick CG, Zahavi E, Shir Y. A randomized trial of fluoxetine versus amitriptyline in musculo-skeletal pain. Isr J Psychiatry Relat Sci. 2001;38:88-94.
21. Tréves R, Montaine de la Roque P, Dumond JJ, Bertin P, Arnaud M, Desproges-Gotteron R. Prospective study of the analgesic action of clomipramine versus placebo in refractory lumbosciatica (68 cases). Rev Rhum Mal Osteoartic. 1991;58:549-552.
22. Ward N, Bokan JA, Phillips M, Benedetti C, Butler S, Spengler D. Antidepressants in concomitant chronic back pain and depression: doxepin and desipramine compared. J Clin Psychiatry. 1984;45:54-57.
23. Dworkin RH, Turk DC, Peirce-Sandner S, et al. Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain. 2010;149:177-193.
24. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113:9-19.
25. Turk DC, Dworkin RH, Allen RR, et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain. 2003;106:337-345.
26. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105-121.
27. Dworkin RH, Turk DC, McDermott MP, et al. Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. Pain. 2009;146:238-244.
28. Skljarevski V, Desaiah D, Liu-Seifert H, et al. Efficacy and safety of duloxetine in patients with chronic low back pain. Spine (Phila Pa 1976). 2010a;35:E578-E585.
29. Skljarevski V, Ossanna M, Liu-Seifert H, et al. A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. Eur J Neurol. 2009;16:1041-1048.
30. Skljarevski V, Zhang S, Desaiah D, et al. Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial. J Pain. 2010b;11:1282-1290.
31. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23:129-138.
32. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis. Chichester, U.K.: Wiley-Blackwell; 2009.
33. Dharmshaktu P, Tayal V, Kalra BS. Efficacy of antidepressants as analgesics: a review. J Clin Pharmacol. 2012;52:6-17.
34. Andersen J, Kristensen AS, Bang-Andersen B, Strømgaard K. Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters. Chem Commun (Camb). 2009;25:3677-3692.
35. Virani AS, Bezchlibnyk-Butler KZ, Jeffries JJ, Procyshyn RM. Clinical Handbook of Psychotropic Drugs Online. Göttingen, Germany: Hogrefe Publishing; 2012. http://chpd.hogrefe.com. (accessed October 5, 2013).
36. Dworkin RH, Turk DC, Katz NP, et al. Evidence-based clinical trial design for chronic pain pharmacotherapy: a blueprint for ACTION. Pain. 2011;152(suppl 3):S107-S115.
37. Dworkin RH, Turk DC, Peirce-Sandner S, et al. Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain. 2012;153:1148-1158.
38. Turk DC, Dworkin RH, Burke LB, et al. Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations. Pain. 2006;125:208-215.
39. Turk DC, Dworkin RH, McDermott MP, et al. Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations. Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials. Pain. 2008;139:485-493.
40. Williamson OD, Gabbe BJ, Sutherland AM, Wolfe R, Forbes AB, Cameron PA. Comparing the responsiveness of functional outcome assessment measures for trauma registries. J Trauma. 2011;71:63-68.
41. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nded. Hillsdale, NJ: Lawrence Earlbaum Associates; 1988.
42. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558.
43. Schacht A, Dyachkova Y, Walton JR. Critical evaluation of mixed treatment comparison meta-analyses using examples assessing antidepressants and opioid detoxification treatments. Int J Methods Psychiatr Res. 2013;22:166-174.